JWCA has advised immunogen on capital market transactions with nearly $200 million in transaction value
September 2017: JWCA advises ImmunoGen on an exchange of their 4.50% convertible notes due 2021 into common equity
June 2016: JWCA advises ImmunoGen on its $100 million convertible bond offering